Protocol 011 at Wk 144: Islatravir + Doravirine in Treatment-Naive Persons With HIV

October 27-30, 2021; London, United Kingdom
In the phase IIb trial, continued high rates of efficacy were seen in the combined ISL plus DOR arm at 144 Weeks; no participants in this arm met criteria for resistance testing.
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: November 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Commentary from Dr Jason Halperin on the use of 2-drug ART for rapid start, from Clinical Care Options (CCO)

Jason Halperin, MD, MPH Released: November 29, 2021

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients with virologic failure and resistance

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021

Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: November 24, 2021

Expert recap of new data on HIV drug resistance from EACS 2021, from Dr Babafemi Taiwo and Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: November 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue